Media headlines about Kala Pharmaceuticals (NASDAQ:KALA) have been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Kala Pharmaceuticals earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave media stories about the company an impact score of 44.9987704526845 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the media stories that may have impacted Accern Sentiment Analysis’s rankings:
- Kala Pharmaceuticals 2017 Q4 – Results – Earnings Call Slides (seekingalpha.com)
- Kala Pharmaceuticals, Inc. (KALA) Q4 2017 Earnings Conference Call Transcript (finance.yahoo.com)
- Kala Pharmaceuticals (KALA) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPS (americanbankingnews.com)
- BRIEF-Kala Pharmaceuticals Posts Q4 Loss Per Share $0.46 (reuters.com)
- Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results (finance.yahoo.com)
Several brokerages have commented on KALA. BidaskClub raised shares of Kala Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, February 16th. Wells Fargo reaffirmed an “outperform” rating and issued a $19.00 price objective (down previously from $24.00) on shares of Kala Pharmaceuticals in a research report on Thursday, January 25th. They noted that the move was a valuation call. Finally, Wedbush reaffirmed an “outperform” rating and issued a $46.00 price objective on shares of Kala Pharmaceuticals in a research report on Friday, December 22nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. Kala Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $35.80.
Kala Pharmaceuticals (NASDAQ:KALA) last posted its quarterly earnings results on Monday, March 26th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.09). research analysts expect that Kala Pharmaceuticals will post -1.93 earnings per share for the current year.
In other Kala Pharmaceuticals news, major shareholder Orbimed Advisors Llc purchased 170,338 shares of the stock in a transaction dated Wednesday, January 10th. The shares were bought at an average price of $12.83 per share, with a total value of $2,185,436.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last three months, insiders bought 1,108,150 shares of company stock worth $15,772,394.
Kala Pharmaceuticals Company Profile
Kala Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program.
Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.